 "Dr Reddy's seeks to revamp generics biz after remediation with USFDA flops")
The management at pharmaceutical major, Dr Reddy's Laboratories, has set about trying to bring its house in order, with the considerable time and energy it spent in negotiating an early closure of compliance issues involving USFDA's warning letter having come a cropper.
The company recently announced a series of steps, including the reversal of business decisions taken earlier. Analysts say the measures are a sign the management seeks to break status quo and regain business momentum.
The management stated upfront the reason for its decisions such as the sale of Bristol manufacturing facility and the reversal of a couple of
